PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
43.43%
EBIT growth above 1.5x AXSM's 0.78%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
-14.45%
Negative operating income growth while AXSM is at 0.78%. Joel Greenblatt would press for urgent turnaround measures.
43.33%
Positive net income growth while AXSM is negative. John Neff might see a big relative performance advantage.
43.35%
Positive EPS growth while AXSM is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
43.35%
Positive diluted EPS growth while AXSM is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.17%
Negative OCF growth while AXSM is at 40.48%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-15.15%
Negative FCF growth while AXSM is at 39.95%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-167027.54%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-35848.35%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-39776.52%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-711192.96%
Negative 10Y net income/share CAGR while AXSM is at 38.18%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-12332.31%
Negative 5Y net income/share CAGR while AXSM is 38.18%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-13057.95%
Negative 3Y CAGR while AXSM is 38.18%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
90012.37%
10Y equity/share CAGR above 1.5x AXSM's 2.86%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
5373.91%
5Y equity/share CAGR above 1.5x AXSM's 2.86%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
7310.97%
3Y equity/share CAGR above 1.5x AXSM's 2.86%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
164.96%
Positive asset growth while AXSM is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
955.36%
BV/share growth above 1.5x AXSM's 100.00%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-33.08%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
0.44%
R&D dropping or stable vs. AXSM's 5.10%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
34.62%
We expand SG&A while AXSM cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.